

## PURPOSE OF BILL: SB 331

To create the genetic testing act and for other purposes.

## ACTUARIAL STATEMENT

The Fiscal Impact Statement was prepared according to generally accepted actuarial principles and practices, in compliance with ACT 112. The Statement provides an estimate of the financial and actuarial effect of the proposed change(s) on the Plans, if possible. The Statement makes no comment or opinion with regard to the merits of the measure for which the Statement is prepared; however, any identified technical or mechanical defects have been noted.

We have reviewed the input and results of our analysis for reasonableness and relied upon the data and information provided by the Plans and their Claims Processing Contractors.

A handwritten signature in black ink, appearing to read "Patrick Klein".

4/15/2025

---

Patrick Klein, FSA, MAAA  
Vice President, Segal

---

Date

A handwritten signature in black ink, appearing to read "Matthew Kersting".

4/15/2025

---

Matthew Kersting, FSA, MAAA  
Vice President, Segal

---

Date

## PROJECTED COSTS

Plan	Plan Design Change	Estimated Impact
EBD	No Change	No impact

## PRICING APPROACH AND COMMENTS

SB 331 requires health benefit plans offer in the state to cover clinical genetic testing for an inherited cancer mutation for an enrollee with a personal or family history of cancer if the clinical genetic testing for a clinical genetic testing for an inherited cancer mutation is recommended by a healthcare professional. Also requires evidenced-based cancer imaging for an enrollee with an increased risk of cancer as recommended by National Comprehensive Cancer Network clinical practice guidelines.

(5)(B)(x) excludes the requirement for any state or local government employee plan. Because EBD is a state employee plan this bill would have no impact.